New Patents xvii

Nifedipine is a well-known calcium antagonist, and salbutamol is a much used bronchodilator. Yet a pharmaceutical combination containing both substances is not known. Prior experience with the administration of nifedipine in com- bination with beta2-sympathomimetica did not make any combinatory effect appear probable. It was further to be feared that any combinatory effect would be accompanied by correspon- dingly increased side effects. The new pharma- ceutical composition is nevertheless intended to provide a combination of nifedipine with a beta2-sympathomimeticum usable for systemic application especially in cases of asthmatic dis- eases. According to the invention, the pharma- ceutical combination contains salbutamol besides nifedipine. The combined effect of the active substances is super-additive and syn- ergistic. Nevertheless, no addition of side effects is experienced. The therapeutic effect of the com- bination corresponds approximately to the maximum achievable improvement.

4871725

I-METHYL-15 ALPHA-(I- OXYALKYL)ANDROSTA- 1

4-DIENE-3,17-DIONES, PROCESSES FOR THEIR

PRODUCTION, AND PHARMACEUTICAL

PREPARATIONS CONTAINING THEM

Ulrich Kerb, Yukishig Nishino, David Hender- son, Berlin, Federal Republic Of Germany as- signed to Schering Aktiengesellschaft

l-Methyl-15 alpha-(1-oxyalkyl)androsta-I 4- diene-3,17-diones of general Formula I See Pa- tent for Chemical Structure (I) wherein RI is a hydrogen atom or an acyi group of 1-10 carbon atoms, R2 is an OR4, NHR5 or an S(O)nR6 group, R4 being straight- or branched-chain alkyl group of 1-10 carbon atoms, R5 being an acyl group of 1-10 carbon atoms, R6 being a straight- or branched-chain alkyi group of 1-10 carbon atoms or an aryl group of 6-10 carbon atoms, R3 is a hydrogen atom or a straight- or branched-chain alkyl group of 1-8 carbon atoms, and n is 0, 1 or 2, are suitable as inhibitors of estrogen biosynthesis for fertility control and for the treatment of diseases that are evoked by estrogens.

4871723

METHOD FOR TREATING PSORIASIS BY EXTERNALLY

ADMINISTERING TO A PATIENT A PHARMACEUTICAL

COMPOSITION CONTAINING ACTIVE-TYPE VITAMIN D

Yuj Makino, Yoshik Suzuki, Takash Aoyagi, Hino, Japan assigned to Teijin Limited

A process for treating psoriasis by externally ap- plying to the skin of a warm-blooded animal a composition comprising: (A) a pharmaceutically effective amount of an active-type vitamin D3, (B) a substantially water-free carrier containing the active-type vitamin D3 dissolved or uniformly dispersed therein, and (C) a solvent selected from fatty acid esters, higher alcohols with 10 or more carbons and propylene car- bonate.

4871728

PHARMACEUTICAL COMPOSITION COMPRISING AN ORGANIC ZINC COMPLEX AND

A PROCESS FOR PREPARING THE ACTIVE SUBSTANCE

Gyula Sebestyen, Istvan Simonyi, Gizeil Miholics, Marta Kovacs, Frigyes Gorgenyi, Marton Fekete, VagoPal , Istva Seres, Janos Egri, Maria Szeli, Budapest, Hungary assigned to EGIS Cyogyszergvar

The invention refers to a novel pharmaceutical composition having especially antimycotic ac- tivity and comprising the zinc complex of 5- chloro-7-iodo-8 hydroxyquinoline of formula (I) See Patent for Chemical Structure (I) and one or more pharmaceutically acceptable carriers. The pharmaceutical composition of the invention can be used for the effective treatment of mycotic infections on the skin surface, mucous mem- branes or nails. The complex of formula (I) is